GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Equity-to-Asset

Savara (Savara) Equity-to-Asset : 0.79 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Savara Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Savara's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $140.37 Mil. Savara's Total Assets for the quarter that ended in Dec. 2023 was $177.56 Mil.

The historical rank and industry rank for Savara's Equity-to-Asset or its related term are showing as below:

SVRA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.24   Med: 0.75   Max: 0.83
Current: 0.79

During the past 13 years, the highest Equity to Asset Ratio of Savara was 0.83. The lowest was -1.24. And the median was 0.75.

SVRA's Equity-to-Asset is ranked better than
66.28% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs SVRA: 0.79

Savara Equity-to-Asset Historical Data

The historical data trend for Savara's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Equity-to-Asset Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.66 0.82 0.77 0.79

Savara Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.76 0.73 0.81 0.79

Competitive Comparison of Savara's Equity-to-Asset

For the Biotechnology subindustry, Savara's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Savara's Equity-to-Asset falls into.



Savara Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Savara's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=140.372/177.564
=

Savara's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=140.372/177.564
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Savara  (NAS:SVRA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Savara Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Savara's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121